CN113332193A - 一种预防妊娠纹的组合物和按摩霜 - Google Patents
一种预防妊娠纹的组合物和按摩霜 Download PDFInfo
- Publication number
- CN113332193A CN113332193A CN202110553532.8A CN202110553532A CN113332193A CN 113332193 A CN113332193 A CN 113332193A CN 202110553532 A CN202110553532 A CN 202110553532A CN 113332193 A CN113332193 A CN 113332193A
- Authority
- CN
- China
- Prior art keywords
- parts
- preventing
- oil
- palmitoyl
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010040925 Skin striae Diseases 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 208000031439 Striae Distensae Diseases 0.000 title claims abstract description 39
- 239000006071 cream Substances 0.000 title claims abstract description 34
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims abstract description 19
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims abstract description 19
- -1 palmitoyl hexapeptide-11 Chemical compound 0.000 claims abstract description 18
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 17
- 108010087806 Carnosine Proteins 0.000 claims abstract description 17
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 108010047657 Phe-Val-Ala-Pro-Phe-Pro Proteins 0.000 claims abstract description 17
- 229940044199 carnosine Drugs 0.000 claims abstract description 17
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 17
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 12
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 12
- 239000011732 tocopherol Substances 0.000 claims abstract description 12
- 229930003799 tocopherol Natural products 0.000 claims abstract description 12
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 12
- 229960001295 tocopherol Drugs 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 12
- 235000014121 butter Nutrition 0.000 claims abstract description 8
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000003995 emulsifying agent Substances 0.000 claims description 10
- 239000003974 emollient agent Substances 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000002562 thickening agent Substances 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 4
- 229960003237 betaine Drugs 0.000 claims description 4
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical group CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims description 3
- 229940043234 carbomer-940 Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000010497 wheat germ oil Substances 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 244000144725 Amygdalus communis Species 0.000 claims description 2
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 2
- ZNJFBWYDHIGLCU-UHFFFAOYSA-N jasmonic acid Natural products CCC=CCC1C(CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-UHFFFAOYSA-N 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 241001092489 Potentilla Species 0.000 claims 1
- 239000000828 canola oil Substances 0.000 claims 1
- 235000019519 canola oil Nutrition 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 41
- 230000000694 effects Effects 0.000 abstract description 28
- 102000008186 Collagen Human genes 0.000 abstract description 17
- 108010035532 Collagen Proteins 0.000 abstract description 17
- 229920001436 collagen Polymers 0.000 abstract description 17
- 210000002950 fibroblast Anatomy 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- 210000004207 dermis Anatomy 0.000 abstract description 5
- 208000003251 Pruritus Diseases 0.000 abstract description 4
- 230000035935 pregnancy Effects 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 210000000651 myofibroblast Anatomy 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 12
- 230000006872 improvement Effects 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000013521 mastic Substances 0.000 description 6
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 5
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 5
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 5
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 5
- 229940022757 asiaticoside Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 239000004863 Frankincense Substances 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000003717 Boswellia sacra Nutrition 0.000 description 3
- 240000007551 Boswellia serrata Species 0.000 description 3
- 235000012035 Boswellia serrata Nutrition 0.000 description 3
- 241000167550 Centella Species 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000010495 camellia oil Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 2
- 241001135917 Vitellaria paradoxa Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 229940116978 human epidermal growth factor Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940057910 shea butter Drugs 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- HMMGKOVEOFBCAU-BCDBGHSCSA-N 3-Acetyl-11-keto-beta-boswellic acid Chemical compound C1C[C@@H](OC(C)=O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC(=O)[C@@H]3[C@]21C HMMGKOVEOFBCAU-BCDBGHSCSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HMMGKOVEOFBCAU-UHFFFAOYSA-N AKBA Natural products C1CC(OC(C)=O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CC(=O)C3C21C HMMGKOVEOFBCAU-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- NXTGWOGJZSSREB-HJXLNUONSA-N C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 Chemical compound C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 NXTGWOGJZSSREB-HJXLNUONSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 241000519590 Pseudoalteromonas Species 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 240000008530 Rosa canina Species 0.000 description 1
- 235000000539 Rosa canina Nutrition 0.000 description 1
- 235000010337 Rosa dumalis Nutrition 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- SWQUTKGVXGTROS-UHFFFAOYSA-N bis(2-ethoxyethyl) butanedioate Chemical compound CCOCCOC(=O)CCC(=O)OCCOCC SWQUTKGVXGTROS-UHFFFAOYSA-N 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940119676 diethoxyethyl succinate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035161 fibroblast apoptotic process Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000008132 rose water Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000009891 weiqi Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于日化领域,其公开了一种预防妊娠纹的组合物,包括如下重量份组分:肌肽:0.1‑0.5;积雪草提取物:0.5‑2.0;棕榈酰三肽‑5:0.01‑0.1;棕榈酰六肽‑11:0.01‑0.1;乳香油:0.1‑0.5;生育酚:0.1‑2.0;透明质酸:0.3‑0.5。所述组合物对于妊娠时期的妊娠纹皮肤,具有很好的预防和舒缓修复功效,能调节成纤维细胞活性,可促进真皮层的胶原蛋白和肌成纤维细胞的生成,缓解预防妊娠纹的形成和舒缓,同时能滋养肌肤、增加弹性,使皮肤摆脱干痒长纹等功效。同时还公开了一种按摩霜。
Description
技术领域
本发明涉及日化领域,特别是一种预防妊娠纹的组合物和按摩霜。
背景技术
妊娠纹也称为膨胀纹,由青紫色的条纹至白色萎缩条纹并伴有珍珠般的光泽发展趋势,妊娠纹主要出现在腹部隆起皮肤,还可能发生在手臂、胸部、后腰、臀部以及大腿内外侧;通常在女性孕期第三个月开始出现,第五个月及第六个月时是妊娠纹产生的高频期。
妊娠纹的产生主要由于皮肤表皮层和真皮层因腹部不断隆起逐渐拉伸而产生损伤,导致真皮层的结缔组织损伤,破坏胶原纤维和弹性纤维,引起病灶处伸展性和弹性减弱,从而引发条纹状皮损。同时孕期体内的雄性激素、糖皮质激素的增加,而糖皮质激素增加会使弹性蛋白分解变性并抑制成纤维细胞的活性和增殖,从而减少胶原蛋白、弹性蛋白、胶原纤维和网状纤维等基质成分的合成,其中成纤维细胞是真皮细胞中主要的成分,对皮肤伤口愈合过程和瘢痕形成有重要的意义,皮肤真皮层因成纤维细胞的变性而变得更加的脆弱敏感,因此更容易因受到机械拉伸和炎症的影响而紊乱、甚至断裂。
妊娠纹一旦产生,让其自然完全愈合几乎不可能,妊娠纹虽然对于患者身体健康无威胁,但是会影响皮肤美观,给患者带来极大的精神压力和心理负担,严重的可能导致心理疾病的发生。
目前常见的祛妊娠纹方法主要是化学修复成分和物理治疗其中一者或结合,其中两者结合居多,还包括化学剥脱法,具体的如下:利用化学剥脱原理涂抹一定浓度的乙醇酸,但一般使用浓度高、刺激性大,容易引起皮肤灼伤,危险性大;物理仪器治疗如频射利用电磁波原理、激光疗法(585nm脉冲染料激光)是利用不同波长的光谱光源原理,而妊娠纹霜是提供化学修复成分的重要环节,当下主要运用于妊娠纹霜的修复成分包含可可脂、茶籽油、积雪草、胶原蛋白、橄榄油等等。
积雪草中的有效成分为积雪草甘,古文《唐本草》记载,积雪草可“捣敷热肿丹毒。现代药理学研宄证明,积雪草甘有明显的抗炎作用,对妊娠纹的治疗具有切实的效果,对于伤口愈合障碍也有积极作用,还有研宄表明积雪苷可刺激成纤维细胞和抑制糖皮质激素,可降低并且预防妊娠纹的生成。
对于皮肤损伤,活血化腐是促进皮肤愈合的核心,而中医单味药使用最高之一的就是乳香,乳香具有抗炎、抗溃疡,抗氧化,抗菌等等以及有促进伤口愈合、抗焦虑、抗抑郁、抗凝血以及促神经再生等多种生物活性。
CN109044888A公开了茶籽油祛妊娠纹滋润霜及其制备方法,该专利是以茶籽油和人表皮生长因子为主要功效成分,再配以其他原料。以上技术含有现禁用物质人表皮生长因子,存在一定的安全隐患。
CN201810082053.0公开了一种具有有效预防及祛除妊娠纹功效的修复霜,包括如下重量百分比组分:黑加仑籽油3~6%;牛油果树果脂2~4%;油橄榄果油3~6%;可可脂2~4%;祛妊娠纹组合物117.5%~35%,祛妊娠纹组合物29%~22%。其中祛妊娠纹组合物1由甲基硅烷醇羟脯氨酸酯天冬氨酸酯5%~10%;胶原蛋白2.5%~5%;β-葡聚糖10%~20%组成;祛妊娠纹组合物2由假交替单胞菌发酵产物提取物3%~10%;乙酰基三肽-13%~6%;积雪草提取物2%~4%;寡肽-11%~2%组成。该发明的优点在于:有效预防和解决妊娠纹、疤痕断裂的再生链接和修复困难的问题,让其皮肤新生的修复霜。
该方案公开了积雪草提取物、多肽对于妊娠纹的预防和修复的作用。
CN201910324492.2公开了一种预防妊娠纹磨砂膏及其制备方法,主要由积雪草提取物、扭刺仙人掌茎提取物、棕榈酰五肽-4、棕榈酰四肽-7、肌肽、三肽-1铜、混合纤维素磨砂粒子制备而成;其制备方法:将透明质酸钠、卡波姆预分散于甘油和部分丁二醇中,得到第一混合物;取余量丁二醇、对羟基苯乙酮及己二醇混合溶解、均匀得到第二混合物;将第一混合物和纯化水均质搅拌;加入第二混合物搅拌;加入琥珀酸二乙氧基乙酯、甜菜碱、积雪草提取物、扭刺仙人掌茎提取物、棕榈酰五肽-4、棕榈酰四肽-7、肌肽、三肽-1铜搅拌;加入氢氧化钠,调节pH,加入纤维素磨砂粒子搅拌得到成品。该发明能温和按摩妊娠纹,祛除表皮角质使多肽等物质通过表皮吸收。
该方案公开了棕榈酰多肽特别是棕榈酰五肽-4、棕榈酰四肽-7对于妊娠纹的预防和修复的效果。同时记载了棕榈酰多肽和肌肽组合来达到上述目的。
CN201910191562.1公开了一种祛除妊娠纹的膏霜及其制备方法,膏霜包括皮肤调理剂,所述皮肤调理剂在膏霜中的重量百分含量为:羟基脯氨酯硅烷醇1~5%、复合神经酰胺Total Cera 0.1~0.5%、寡肽-1 0.1~1%、由积雪草苷、羟基积雪草甙组成的复合物0.1~0.3%、由棕榈酰五肽-4、棕榈酰四肽-7、棕榈酰三肽-1、棕榈酰三肽-5、三肽-1、六肽-9组成的复合物1~5%、由咖啡因、硅氧烷三醇藻酸酯、丁二醇组成的复合物3~6%、牛油果树果脂油1~5%、由红藻门藻提取物、褐藻提取物组成的复合物0.1~1%和海绵微针0.1~1%。该膏霜能够显著提升妊娠纹部位弹性、妊娠纹部位均匀度、妊娠纹部位粗糙度、减小妊娠纹和淡化妊娠纹的效果。
该方案公开了棕榈酰五肽-4、棕榈酰四肽-7、棕榈酰三肽-1、棕榈酰三肽-5在妊娠纹上的预防和治疗方面的应用。
CN201910329578.4公开了一种妊娠纹淡化修复乳及其制备方法,由以下组分制成:聚甘油-3甲基葡糖二硬脂酸酯,鲸蜡硬脂醇,油橄榄果油,野蔷薇果油,塔希提栀子花油,生育酚,甘油,丁二醇,透明质酸钠,丙烯酸酯类/C10-30烷醇丙烯酸酯交联聚合物,对羟基苯乙酮,1,2-己二醇,三乙醇胺,积雪草提取物,棕榈酰五肽-4及千叶玫瑰花水;其制备方法步骤:取原料制得第一至第三混合物;将第一、第二混合物混合匀质搅拌制得第四混合物;在第四混合物中加入第三混合物,积雪草提取物,棕榈酰五肽-4搅拌得到成品。本发明对妊娠纹达到更舒缓修复功效。
上述方案主要集中在棕榈酰多肽、肌肽、积雪草提取物等方面研究妊娠纹的预防和治疗效果。
本案的研究重点在于从机理上通过实验证实妊娠纹的预防效果和哪些因素相关,进而从配方上进行优化,从预防的角度上解决妊娠纹的问题。
所以本案要解决的技术问题集中在:
1、现有的预防妊娠纹技术对于预防妊娠纹效果不显著;
2、暂时没有针对性的依据妊娠纹生成原理研制的预防护肤产品;
3、早期有效的预防修复妊娠纹的生成和加重,能从根源解决问题。
发明内容
本发明旨在提供一种预防妊娠纹的组合物,该组合物含多种修复妊娠纹成分、不含矿油、矿脂、有效预防妊娠纹的生成、缓解舒缓已有妊娠纹。
所述组合物对于妊娠时期的妊娠纹皮肤,具有很好的预防和舒缓修复功效,能调节成纤维细胞活性,可促进真皮层的胶原蛋白和肌成纤维细胞的生成,缓解预防妊娠纹的形成和舒缓,同时能滋养肌肤、增加弹性,使皮肤摆脱干痒长纹等功效。
在不做特殊说明的情况下,本发明的%、份均为重量百分百和重量份。
其具体方案为:一种预防妊娠纹的组合物,包括如下重量份组分:
肌肽:0.1-0.5;
积雪草提取物:0.5-2.0;
棕榈酰三肽-5:0.01-0.1;
棕榈酰六肽-11:0.01-0.1;
乳香油:0.1-0.5;
生育酚:0.1-2.0;
透明质酸:0.3-0.5。
在本发明中,各物质的单独功效如下:
肌肽:是由β-丙氨酸和L-组氨酸组成的一种二肽,在化妆品应用中被证实可以起到抗糖基化作用,糖基化反应是糖与蛋白质之间的交联反应,最终会导致非常规的产物:AGEs(糖基化终末产物),AGEs是相互交联的蛋白质,AGEs对细胞有毒性,糖基化过程中胶原蛋白的交联会导致皮肤硬化和皱纹的增加,而肌肽还能减少胶原蛋白被降解,保护皮肤免受其他损失。
积雪草提取物:大量临床试验证实积雪苷能促进创面愈合、加快表皮修复、抑制瘢痕、刺激肉芽生长,机理包括降低免疫反应、封闭血管、促进成纤维细胞凋亡、激活上皮细胞等方面;在体外实验中发现积雪苷能调动细胞到达伤口处,可以提高成纤维细胞DNA的合成量,促进成纤维细胞的增值,并且可以促进成纤维细胞胶原蛋白的合成且呈现剂量依赖关系,并能抑制MMP-1和MMP-9的表达释放,减少胶原蛋白被降解的可能。
棕榈酰三肽-5:具有与人体机体自身机制相似的特定的序列,能够激活转化生长因子(TGF-β)从而产生胶原蛋白,TGF-β能够诱导纤维化反应,促进大多数肌成纤维细胞表达类似a平滑肌肌动蛋白((α-smooth muscle actin,α-SMA),对伤口愈合收缩和瘢痕形成有重要的影响。因此棕榈酰三肽-5能促进皮肤补充缺失的胶原蛋白,从而修复受损皮肤。
棕榈酰六肽-11:棕榈酰六肽-11同时作用于真皮层中的成纤维细胞,促进胶原蛋白、弹性蛋白和细胞外基质成分的合成增加I型胶原蛋白、IV型胶原大白、黏连蛋白-5、整联蛋白的合成,促进表皮细胞的分化成熟、对于皮肤修复有高效的作用,同时还可以促进皮肤细胞外基质的相关基因表达,促进成纤维细胞合成胶原蛋白、弹性蛋白,从而达到增强皮肤弹性,祛皱紧致,还可以增加细胞间的粘附力。
乳香油:乳香油中的主要成分之一11-羰基-β-乙酰乳香酸(AKBA)能有效的抑制基质金属蛋白酶MMPS的分泌作用,促进细胞外基质,有助于细胞的迁移和增殖。同时乳香的辛醇能增加透皮吸收药物在角质层的溶解度脱去角质层脂质,影响角质层的有序排列;乳香中的萜(烯)类还能提高组织电导率,打开角质层的极性孔道,增加药物从基质向角质层的分配。乳香能抑制基质金属蛋白酶的分泌,促进伤口修复,并且还能有效地协助其他药效物质的透皮吸收,更好的发挥了其他物质的功效作用。
生育酚:维生素E可作为免疫调节物来调节细胞调节素、前列腺素、凝血素及促细胞生长素的合成。
透明质酸:透明质酸可以诱导成纤维细胞增殖合成胶原,并调控胶原的组排方式。
本案经过大量探索发现,本申请中的组合物能很好的发挥协同增效作用,达到很好的预防和舒缓修复妊娠纹的生长。
在上述的预防妊娠纹的组合物中,包括如下重量份组分:
肌肽:0.15-0.45;
积雪草提取物:0.6-1.8;
棕榈酰三肽-5:0.02-0.08;
棕榈酰六肽-11:0.02-0.08;
乳香油:0.2-0.4
生育酚:0.3-1.8;
透明质酸:0.35-0.45。
在上述的预防妊娠纹的组合物中,包括如下重量份组分:
肌肽:0.2-0.4;
积雪草提取物:0.8-1.6;
棕榈酰三肽-5:0.04-0.06;
棕榈酰六肽-11:0.04-0.06;
乳香油:0.25-0.35;
生育酚:0.8-1.4;
透明质酸:0.35-0.45。
在本案中,肌肽含量为0.1-0.5份,例如可以是0.1份、0.15份、0.2份、0.25份、0.3份、0.35份、0.4份、0.45份、0.5份等。
乳香油含量为0.1-0.5份,例如可以是0.1份、0.15份、0.2份、0.25份、0.3份、0.35份、0.4份、0.45份、0.5份等。
透明质酸含量为0.3-0.5份,例如可以是0.3份、0.35份、0.4份、0.45份、0.5份等。
积雪草提取物含量为0.5-2.0份,例如可以是0.5份、0.6份、0.80份、1.0份、1.2份、1.4份、1.6份、1.8份、2.0份等。
棕榈酰三肽-5含量为0.01-0.1份,例如可以是0.01份、0.02份、0.04份、0.05份、0.06份、0.07份、0.08份、0.09份、0.1份等。
棕榈酰六肽-11含量为0.01-0.1份,例如可以是0.01份、0.02份、0.04份、0.05份、0.06份、0.07份、0.08份、0.09份、0.1份等。。
生育酚含量0.1-2.0份,例如可以是0.1份、0.2份、0.3份、0.5份、0.8份、1.0份、1.5份、1.8份、2.0份等。
同时,本发明还公开了一种预防妊娠纹的按摩霜,包括如下重量份组分:
如上所述组合物0.5-5份;
纯净水45-75份;
乳化剂1.5-5.0份;
增稠剂0.3-2.0份。
在上述的预防妊娠纹的按摩霜中,还包括如下重量份组分:
润肤剂13.0-20.0份;
保湿剂10-20份;
防腐剂0.4-0.6份;
香精0.001-0.1份。
在本案中,所述组合物含量为0.5-5份,例如可以是0.5份、0.8份、1.0份、1.5份、1.6份、1.8份、2.0份、2.5份、2.8份、3.0份、3.5份、4.0份、4.5份、5.0份等等。
所述的纯净水含量为45-75份,例如可以是45份、50份、55份、60份、62份、65份、70份、72份、75份等等。
所述的乳化剂含量为1.5-5.0份,例如可以是1.5份、、2.0份、2.5份、2.8份、3.0份、3.5份、4.0份、4.5份、5.0份等等。
所述的增稠剂含量为0.3-2.0份,例如可以是0.3份、0.5份、0.8份、1.0份、1.2份、1.5份、1.8份、2.0份等等。
所述的润肤剂含量为13.0-20.0份,例如可以是13份、14份、15份、16份、17份、18份、19份、20份等等。
所述的保湿剂含量为10.0-20.0份,例如可以是10份、11份、12份、14份、15份、16份、17份、18份、19份、20份等等。
所述的香精含量为0.001-0.1份,例如可以是0.001份、0.005份、0.008份、0.01份、0.02份、0.04份、0.06份、0.08份、0.10份等等。
在上述的预防妊娠纹的按摩霜中,所述乳化剂包括燕麦乳化剂、CARE-450、魅力峰、EM-90、MON-L、A-165、M68、SP-60、单甘脂、1618醇、SSE-20或SS中的任意一种或至少两种的组合。
在上述的预防妊娠纹的按摩霜中,所述增稠剂包括卡波940、U21、2020、AVC、EG或汉生胶中的任意一种或至少两种的组合。
在上述的预防妊娠纹的按摩霜中,所述润肤剂为2-EHP、GTCC、TIO、DC200/100cst或DC200/350cst、DC345、1403、1020、或者低芥酸菜籽油、小麦胚芽油、白池花籽油、金色霍霍巴油中、甜杏仁油中的任意一种或至少两种以上的组合;
所述保湿剂包括甘油、丙二醇、丁二醇、甲基丙二醇、山梨醇、聚乙二醇、己二醇、甜菜碱或戊二醇中的任意一种或至少两种的组合;
所述防腐剂为馨酰酮。
在上述的预防妊娠纹的按摩霜中,采用如下方法制备得到:
(1)将溶剂纯净水、增稠剂和保湿剂在80-90℃下进行水相混合搅拌,得到水相混合液;将乳化剂、润肤剂在75-85℃下进行油相混合搅拌,得到油相混合液;
(2)将步骤(1)得到的水相混合液和油相混合液在75-85℃下混合均质,得到均质液;
(3)降温至40-45℃后,加入防腐剂和修复组分混合,得到所述预防妊娠纹按摩霜。
优选地,步骤(1)所述水相混合搅拌的温度为80-90℃,例如可以是80℃、81℃、82℃、83℃、84℃、85℃、86℃、87℃、88℃、89℃、90℃等。
优选地,步骤(1)所述油相混合搅拌的温度为75-85℃,例如可以是75℃、76℃、77℃、78℃、79℃、80℃、81℃、82℃、83℃、84℃、85℃等。
优选地,步骤(2)所述混合均质的温度为80-85℃,例如可以是80℃、81℃、82℃、83℃、84℃、85℃等。
优选地,步骤(3)所述加入防腐剂和修复组分混合的温度为40-45℃,例如可以是40℃、41℃、42℃、43℃、44℃、45℃等。
本发明的有益效果在于:
本发明所述组合物各组分相互配合,具有高效显著的协同增效作用,对于皮肤干痒、敏感、长妊娠纹的女性,具有很好的预防和舒缓皮肤不适以及减缓妊娠纹的生长作用,能够滋润皮肤、抑制糖皮质激素、提高细胞活性,促进胶原蛋白的生成和协助伤口的愈合、减缓胶原沉积带来的活性不足、缓解肌肤干痒、在修复过程中为上皮组织提供必须的养分,促进皮肤修复。添加本发明所述修复组合物制得的预防妊娠纹按摩霜能达到从内部肌肤底层促进胶原蛋白合成,表层营养舒缓滋润,令肌肤光泽健康无纹。
本发明的按摩霜肤感丰盈易推开,拥有良好的按摩感,按摩后可以有效的提高皮肤柔软度、温和滋润,并且对于皮肤有很好的修复和保护作用,长期使用能提高皮肤弹性力、皮肤的屏障能力,能更好的预防和舒缓修复妊娠纹。
具体实施方式
下面结合具体实施方式,对本发明的技术方案作进一步的详细说明,但不构成对本发明的任何限制。
原材料说明
肌肽来源于:Symrise Shanghai Ltd.德之馨(上海)有限公司
积雪草提取物来源于:广西昌洲天然产物开发有限公司公司
棕榈酰三肽-5来源于:荷兰皇家帝斯曼集团
棕榈酰六肽-11来源于:深圳市维琪生物科技有限公司
乳香油来源于:法国ALBERT VIEILLE
生育酚来源于:巴斯夫新材料有限公司
透明质酸来源于:山东福瑞达医药集团有限公司
实施例1
一种预防妊娠纹的按摩霜中,采用如下方法制备得到:
(1)将溶剂纯净水、增稠剂(AVC、汉生胶)、保湿剂(甘油、丁二醇、甜菜碱、1,2-己二醇、PEG-400)在85℃下进行水相混合搅拌,得到水相混合液;将乳化剂(魅力峰、M68、A-165、1618醇)、润肤剂(低芥酸菜籽油、TIO、小麦胚芽油、1403、DC345)在80℃下进行油相混合搅拌,得到油相混合液;
(2)将步骤(1)得到的水相混合液和油相混合液在82℃下混合均质,得到均质液;
(3)降温42℃后,加入修复组分和防腐剂混合,得到所述按摩霜。
本实施例的配方表如下表1:
表1
实施例2-6
与实施例1大体相同,不同的是修复组分的配比有所不同,其中修复组分总重为2.5重量份,其各组分参考如表2所示的重量比:
表2
实施例7-10
与实施例1大体相同,不同的是,修复组分用量有所区别,其中,实施例7-10的修复组分的各成分比例可参考实施例4。
修复组分的用量参考表3。
表3
实施例7 | 实施例8 | 实施例9 | 实施例10 | |
修复组分重量份 | 0.5 | 1 | 3 | 5 |
对比例1-5
参考实施例1,修复组分用量和实施例1相同,不同的是,修复组分中各成分有所区别,如下表4
表4
对比例1 | 对比例2 | 对比例3 | 对比例4 | 对比例5 | |
肌肽 | 0 | 0.3 | 0.3 | 0.3 | 0.3 |
积雪草提取物 | 1 | 1 | 1 | 1 | 0 |
棕榈酰三肽-5 | 0.05 | 0 | 0.05 | 0.05 | 0.05 |
棕榈酰六肽-11 | 0.05 | 0.05 | 0 | 0.05 | 0.05 |
乳香油 | 0.25 | 0.25 | 0.25 | 0 | 0.25 |
生育酚 | 1 | 1 | 1 | 1 | 1 |
透明质酸 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
对比例6
与实施例4配方大体一致,将棕榈酰三肽-5和棕榈酰六肽-11采用棕榈酰三肽-1和六肽-9替换,用量不变。
测试方法:
试验资料及材料:按摩霜
志愿者纳入标准:所有志愿者均符合以下纳入标准与排除标准。纳入标准:①明确诊断为妊娠纹;②志愿者对本研究知情同意,签署相关文件。排除标准:光过敏;孕期(参与本项研究期间应避孕);高血压或血压未能控制良好者;卟啉症者;癌性病变或疑似癌性病变者;心肺肝肾功能不全及出血性疾病或明显出血倾向者;慢性溶血性贫血者;起博器携带者;近期服用过光敏剂者;自身免疫性疾病者;白化病者;急性化脓性炎症者;闭塞性脉管炎者;重度动脉硬化者;局部感觉或循环障碍者;高热者;医疗部门不建议照射红光者;正参加其他临床研究或预临床验证的体验者;研究人员认为不适合本项目的参与者
测试仪器设备:
皮肤弹性测试仪CT-cutometer dual MPA 580,是基于吸入法的原理,通过负压使皮肤机械的变形来测试皮肤粘弹性的仪器。
MX-皮肤黑色素和血红素测试仪Mexameter MX18,其特殊探头发射三种波长的光,基于吸收原理可以确定皮肤的黑色素含量和血红素(红斑)的含量。
摄影设备佳能EOS 80D最高分辨率6000×4000,每次照片拍摄处于同一光源、拍摄模式、角度、高度,后期使用图像分析软件处理。
电脑设备华为MateBook D15
功效测评流程:
测试环境:恒温独立环境(22±1℃),相对湿度50±5%的环境中静坐30-60分钟。
采用前后对照法、空白对照法,试验时间为56天。分别在试验0天以及试验28天、56天回访。
观察指标:
弹性数值、黑色素以及血红素数值变化、图像。
主要评价指标:
总分0~4分为基本治愈;总分5~9分为显效;总分10~11分为有效;总分12~14分为轻微有效;总分≥15分为无效。治疗总有效率=(基本治愈+显效+有效+轻微有效)/总例数×100%。
数据评价指标:
R2值:皮肤弹性测试仪CT-cutometer dual MPA 580的R2值,与第0天比较改善率≥18%为明显有效提高弹性,改善率12~18%为有效提高弹性,改善率8~12%为基本有效提高弹性,改善率6~10%提高弹性效果不明显,改善率≤5%基本没有提高弹性。
摄像:对使用前后(第0天、第28天、第56天)的妊娠纹皮肤进行摄像,作为客观评价的可循依据。
评分标准:
皮肤表面质地评分:皮肤细腻滋润有弹性=0分、皮肤较润泽、欠细腻=1分,皮肤干燥、稍粗糙=2分,皮肤较干燥,无脱屑=3分,皮肤干燥、脱屑=4分;
妊娠纹深度评分:与正常相平=0分,稍低于正常皮肤=1分,轻度凹陷=3分,深度凹陷=4分;
妊娠纹颜色评分:正常肤色=0分,粉色=1分,红色=2分,浅紫色=3分,深紫色=4分;
妊娠纹面积评分:明显好转=0分,基本好转=1分,稍有好转=2分,轻微好转=3分,基本无变化=4分。
本专利研究共纳入病例32例,2例在使用测试项目时因个人原因中途推出测试治疗,故作为剔除病例,共完成30例。
完成治疗患者为30例,年龄21-38岁,平均(27.33±9.45)岁;产生妊娠纹至今的病程年0-2年,平均(0.93±0.62),产次1-2,平均(1.26±0.40)次,具体资料见表5
表5 来访者基础资料
测试结果可参考表6
表6
结果分析:根据表6数据,在预防及舒缓妊娠纹测试的各项结果数据显示,实施例1、实施例4明显优于对比例1-6;
结论
1、实施例1和4优于对比例1-4,优于对比例5和6,说明积雪草提取物对于配方来说其妊娠纹修复效果影响重大、棕榈酰三肽-1和六肽-9对于妊娠纹的修复作用不可替代棕榈酰三肽-5和棕榈酰六肽-11;
2、单一的榈酰三肽-5或棕榈酰六肽-11效果会优于棕榈酰三肽-1和六肽-9的组合,说明榈酰三肽-5和棕榈酰六肽-11应用于本配方中能够展现较为强大的功效。
3、乳香油的缺失、榈酰三肽-5、棕榈酰六肽-11、肌肽四者重要性大致等同。
4、最优效果的展现,组分中各成分缺一不可。
以上所述的仅为本发明的较佳实施例,凡在本发明的精神和原则范围内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种预防妊娠纹的组合物,其特征在于,包括如下重量份组分:
肌肽:0.1-0.5;
积雪草提取物:0.5-2.0;
棕榈酰三肽-5:0.01-0.1;
棕榈酰六肽-11:0.01-0.1;
乳香油:0.1-0.5;
生育酚:0.1-2.0;
透明质酸:0.3-0.5。
2.根据权利要求1所述的预防妊娠纹的组合物,其特征在于,包括如下重量份组分:
肌肽:0.15-0.45;
积雪草提取物:0.6-1.8;
棕榈酰三肽-5:0.02-0.08;
棕榈酰六肽-11:0.02-0.08;
乳香油:0.2-0.4
生育酚:0.3-1.8;
透明质酸:0.35-0.45。
3.根据权利要求2所述的预防妊娠纹的组合物,其特征在于,包括如下重量份组分:
肌肽:0.2-0.4;
积雪草提取物:0.8-1.6;
棕榈酰三肽-5:0.04-0.06;
棕榈酰六肽-11:0.04-0.06;
乳香油:0.25-0.35;
生育酚:0.8-1.4;
透明质酸:0.35-0.45。
4.一种预防妊娠纹的按摩霜,其特征在于,包括如下重量份组分:
如权利要求1-3任一所述组合物0.5-5份;
纯净水45-75份;
乳化剂1.5-5.0份;
增稠剂0.3-2.0份。
5.根据权利要求4所述的预防妊娠纹的按摩霜,其特征在于,还包括如下重量份组分:
润肤剂13.0-20.0份;
保湿剂10-20份;
防腐剂0.4-0.6份;
香精0.001-0.1份。
6.根据权利要求4所述的预防妊娠纹的按摩霜,其特征在于,所述乳化剂包括燕麦乳化剂、CARE-450、魅力峰、EM-90、MON-L、A-165、M68、SP-60、单甘脂、1618醇、SSE-20或SS中的任意一种或至少两种的组合。
7.根据权利要求4所述的预防妊娠纹的按摩霜,其特征在于,所述增稠剂包括卡波940、U21、2020、AVC、EG或汉生胶中的任意一种或至少两种的组合。
8.根据权利要求5所述的预防妊娠纹的按摩霜,其特征在于,所述润肤剂为2-EHP、GTCC、TIO、DC200/100cst或DC200/350cst、DC345、1403、1020、或者低芥酸菜籽油、小麦胚芽油、白池花籽油、金色霍霍巴油中、甜杏仁油中的任意一种或至少两种以上的组合;
所述保湿剂包括甘油、丙二醇、丁二醇、甲基丙二醇、山梨醇、聚乙二醇、己二醇、甜菜碱或戊二醇中的任意一种或至少两种的组合;
所述防腐剂为馨酰酮。
9.根据权利要求5所述的预防妊娠纹的按摩霜,其特征在于,采用如下方法制备得到:
(1)将溶剂纯净水、增稠剂和保湿剂在80-90℃下进行水相混合搅拌,得到水相混合液;将乳化剂、润肤剂在75-85℃下进行油相混合搅拌,得到油相混合液;
(2)将步骤(1)得到的水相混合液和油相混合液在75-85℃下混合均质,得到均质液;
(3)降温至40-45℃后,加入防腐剂和修复组分混合,得到所述预防妊娠纹按摩霜。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110553532.8A CN113332193A (zh) | 2021-05-20 | 2021-05-20 | 一种预防妊娠纹的组合物和按摩霜 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110553532.8A CN113332193A (zh) | 2021-05-20 | 2021-05-20 | 一种预防妊娠纹的组合物和按摩霜 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113332193A true CN113332193A (zh) | 2021-09-03 |
Family
ID=77470273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110553532.8A Pending CN113332193A (zh) | 2021-05-20 | 2021-05-20 | 一种预防妊娠纹的组合物和按摩霜 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113332193A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3126876A1 (fr) * | 2021-09-15 | 2023-03-17 | Lsi Silderma Ltd | Composition pour prévenir et/ou traiter les vergetures blanches |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070048245A1 (en) * | 2005-09-01 | 2007-03-01 | Belfer William A | Cosmetic composition to accelerate repair of functional wrinkles |
CN101214214A (zh) * | 2008-01-18 | 2008-07-09 | 北京中科雍和医药技术有限公司 | 一种用于妊娠纹修护的复方精油 |
CN108175740A (zh) * | 2018-01-29 | 2018-06-19 | 广州好润生物科技有限公司 | 一种具有有效预防及祛除妊娠纹功效的修复霜及其制备方法 |
WO2020022991A2 (en) * | 2018-05-02 | 2020-01-30 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Topical compositions for stretch marks on the skin |
-
2021
- 2021-05-20 CN CN202110553532.8A patent/CN113332193A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070048245A1 (en) * | 2005-09-01 | 2007-03-01 | Belfer William A | Cosmetic composition to accelerate repair of functional wrinkles |
CN101214214A (zh) * | 2008-01-18 | 2008-07-09 | 北京中科雍和医药技术有限公司 | 一种用于妊娠纹修护的复方精油 |
CN108175740A (zh) * | 2018-01-29 | 2018-06-19 | 广州好润生物科技有限公司 | 一种具有有效预防及祛除妊娠纹功效的修复霜及其制备方法 |
WO2020022991A2 (en) * | 2018-05-02 | 2020-01-30 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Topical compositions for stretch marks on the skin |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3126876A1 (fr) * | 2021-09-15 | 2023-03-17 | Lsi Silderma Ltd | Composition pour prévenir et/ou traiter les vergetures blanches |
EP4151202A1 (fr) | 2021-09-15 | 2023-03-22 | LSI Silderma Ltd | Composition pour prévenir et/ou traiter les vergetures blanches |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080108681A1 (en) | Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions | |
CN108175740B (zh) | 一种具有有效预防及祛除妊娠纹功效的修复霜及其制备方法 | |
CN110013447B (zh) | 一种祛除妊娠纹的膏霜及其制备方法 | |
WO2008139182A2 (en) | Skin care composition | |
WO2018000665A1 (zh) | 一种能让乳房丰满紧致和预防乳腺疾病的精华液 | |
CN110721148A (zh) | 一种多方位提拉紧致多肽精华液及其制备方法 | |
KR20100081509A (ko) | 헤어 컨디셔닝 조성물 | |
US20140302185A1 (en) | Composition for the treatment of skin lesions | |
US9579274B2 (en) | Vitamin C composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same | |
CN108743921A (zh) | 一种预防疤痕形成的修复液及其制备方法和应用 | |
CN114748367A (zh) | 一种保湿修复精华及其制备方法 | |
CN107970140A (zh) | 一种含有鳄鱼油的祛疤组合物及其应用 | |
CN113332193A (zh) | 一种预防妊娠纹的组合物和按摩霜 | |
CN105106033A (zh) | 一种藻蓝蛋白面膜及其制作方法 | |
CN110859758A (zh) | 一种美白抗衰老修复型医用冷敷贴及其制备方法 | |
KR20100082750A (ko) | 이산화탄소 발포 기능성 화장품 조성물 | |
US20100104673A1 (en) | Methods and Compositions for Treatment of Skin Conditions | |
CN108392444A (zh) | 一种微整全能水化妆品及其制备方法 | |
CN113876671A (zh) | 一种含油菜芽提取物的抗衰老组合物及其制备方法 | |
CN109646359B (zh) | 一种具有清洁净化和美容养颜功效的玫瑰木耳泥膜膏及其制备方法 | |
CN112057388A (zh) | 一种用于妊娠纹修复的乳霜及其制备方法 | |
KR102012019B1 (ko) | 튼살 예방 및 치료용 패치 | |
KR20090003828A (ko) | 탈모방지 및 발모 조성물을 함유하는 헤어토닉 | |
RU2805144C1 (ru) | Рекомбинантный ангиогенин в косметических и фармацевтических композициях | |
CN115154533B (zh) | 一种用于治疗黄褐斑的中药组合物及其制备方法、用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |